IVX

INVION FPO [IVX]
Invion Limited, a clinical-stage life sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in Australia. The company develops IVX-PDT, a photosensitising agent to treat a range of cancers, such as skin, prostate, ano-genital, glioblastoma multiforme, lung, and ovarian cancers; and human papilloma virus. It is also involved in the development of INV043, which is in Phase II clinical trial for the treatment of patients with prostate cancer; and in Phase I/II clinical trial to treat non-melanoma skin cancer, as well as for the treatment of oesophageal cancer. The company has collaborations with Hudson Institute of Medical Research, Peter MacCallum Cancer Centre, Dr. I&B Co., Ltd., and Hanlim Pharm Co., Ltd. Invion Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.
Healthcare · ASX Small Cap
$0.0460 +0.0%

Updated 29 Jul 2026 · Signals refresh every scan

Get alerts when IVX triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Track IVX — Free

Active Signals

Bullish Signals

  • Volume surging at 10.3x normal while price falls — heavy selling pressure
  • On a tear — up 12.2% over the last 5 days
  • Beating the Small Ords index — relative strength of 1.35, so it's outpacing the pack
  • Volatility is expanding fast — choppy price action, so buckle up
  • Critical cash runway (0.2 quarters)
  • Pre-revenue with limited cash
  • Near 52-week low (8% of range)
  • Micro-cap ($5-20M) - high risk
  • CANSLIM S: Tight float (42%)
  • Sentiment is mixed — no strong consensus either way
  • This one has been in freefall — down 67% over the past year
  • The bigger volume days are the up days — volume-weighted momentum is positive (1.27%/day)
  • Pre-revenue company — Altman Z-Score not applicable
  • Low-priced stock risk ($0.046)
  • ASX200 bullish (+1.1% 5d)
  • RBA hiking (-3pts)
  • Calendar: Quarterly 4C in 2d (+5pts)

Risk Signals

  • Stochastic is stretched into overbought — could need a breather
  • Below the 200-day average — the long-term trend is still working against it
  • Piotroski F-Score weak (2/9, low-confidence approx)
  • Not enough chatter to gauge sentiment — defaulting to neutral

Recent Catalysts

NONE Notification regarding unquoted securities - IVX
NONE Application for quotation of securities - IVX
NONE Global PDT Leader Dr Colin Hopper Appointed Clinical Advisor

Recent ASX Announcements

2026-06-22 Notification regarding unquoted securities - IVX
2026-06-22 Application for quotation of securities - IVX
2026-06-21 Global PDT Leader Dr Colin Hopper Appointed Clinical Advisor
2026-06-19 Change of Directors' Interest Notices x 3
2026-06-16 Notification regarding unquoted securities - IVX

Key Metrics

$5.0M
Market Cap
45K
Avg Volume
10.3x
Vol Ratio
$0.03 — $0.20
52-Week Range
N/A
Short Interest
N/A
Cash Runway
-111.5%
ROE
N/A
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandpassFloat: 42%
LLeader vs LaggardlaggardRS: -7
IInstitutional Sponsorshipinsufficient_dataInst: 0%
MMarket DirectionpassBullish

Sector: Healthcare

101 tickers in this sector

View all Healthcare signals →Browse all ASX tickers A–Z →
Related Tickers
HIQ -25.0%NOX +22.0%VHL +20.0%EBR +18.4%ICR +16.7%
Compare:IVX vs HIQIVX vs NOXIVX vs VHL
Share this analysis

Track IVX and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required